Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Kim A PappM GooderhamR JenkinsR VenderJ C SzepietowskiT WagnerB HuntB Souberbiellenull nullPublished in: The British journal of dermatology (2018)
GM-CSF blockade is not critical for suppression of key inflammatory pathways underlying psoriasis.